Clinical Trials Browser

Phase 1/2 × Lymphoma, Mantle-Cell × 30 days × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06561425 2026-03-16

Atalanta-1

Phase 1/2 Active not recruiting

130 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03523975 2026-03-13

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Phase 1/2 Recruiting

28 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT04186520 2026-02-23

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Phase 1/2 Recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase 1/2 Completed

97 enrolled 43 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Clinical Trials

CaDAnCe-101

Atalanta-1

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab